Prostate Cancer Highlights

SAN FRANCISCO, CA, USA (UroToday.com) - In a recent issue of the ASCO Post, a NIH panel of experts released a document to guide physicians in their evaluation of active surveillance (AS) of localized prostate cancer.

SAN FRANCISCO, CA, USA (UroToday.com) - The 2012 GU Cancers Symposium sponsored by ASCO, ASTRO and SUO had a record setting attendance with a third of the audience being urologists and nearly 20% radiation oncologists.

SAN FRANCISCO, CA, USA (UroToday.com) -

SAN FRANCISCO, CA, USA (UroToday.com) - Results from ALSYMPCA trial reveal that radium-223 chloride, a local-acting calcium mimetic, significantly prolongs both overall survival and the time to the first skeletal-related event (SRE), compared with placebo, in patients with castration-resistant prostate cancer (CRPC) and bone metastases.

SAN FRANCISCO, CA, USA (UroToday.com) - Researchers from six medical centers investigated the empiric use of the antibiotic (ciprofloxacin 500 mg given twice daily) to treat 77 asymptomatic males with newly elevated PSA (>2.5 ng/ml) undergoing their first prostate biopsy.

SAN FRANCISCO, CA, USA (UroToday.com) - Researchers at UCSF are investigating novel biomarkers to help predict tumor behavior with greater accuracy.

SAN FRANCISCO, CA, USA (UroToday.com) - OGX-427 is a second generation 2’-O-methoxyethyl phosphorothioate (2’-MOE) antisense oligonucleotide.

SAN FRANCISCO, CA, USA (UroToday.com) - Dr. W. Robert Lee expressed the potential advantages of a hypofractionation schedule (using fewer fractions with larger doses per fraction)

SAN FRANCISCO, CA, USA (UroToday.com) - Dr. Gary MacVicar challenged the GU Symposium audience to effectively sequence, combine therapies, and target treatments to men with metastatic CRPC.

SAN FRANCISCO, CA, USA (UroToday.com) - Therapeutic options are to expanding for CRPC.

Prostate Cancer Highlights

More Articles...